CLN8 antibody

Principal name

CLN8 antibody

Alternative names for CLN8 antibody

C8orf61

SwissProt ID

Q5JZQ7 (Canfa), Q6AYM9 (Rat), Q9QUK3 (Mouse), Q9UBY8 (Human)

Gene ID

2055 (CLN8)

Available reactivities

Can (Canine), Hu (Human), Bov (Bovine), Ms (Mouse), Eq (Equine), GP (Guinea Pig), Rt (Rat), Rb (Rabbit)

Available hosts

Rabbit

Available applications

Western blot / Immunoblot (WB)

Background of CLN8 antibody

CLN8 is a transmembrane protein belonging to a family of proteins containing TLC domains, which are postulated to function in lipid synthesis, transport, or sensing. The protein localizes to the endoplasmic reticulum (ER), and may recycle between the ER and ER-Golgi intermediate compartment. Mutations in this gene are associated with progressive epilepsy with mental retardation (EMPR), which is a subtype of neuronal ceroid lipofuscinoses (NCL). Patients with mutations in this gene have altered levels of sphingolipid and phospholipids in the brain. Childhood-onset NCL are a group of autosomal recessive progressive encephalopathies characterized by the accumulation of autofluorescent material, mainly ATP synthase subunit C, in various tissues, notably in neurons. Based on clinical features, the country of origin of patients, and the molecular genetic background of the disorder, at least seven different forms are thought to exist. CLN8 is characterized by normal early development, onset of generalized seizures between 5 and 10 years, and subsequent progressive mental retardation.This gene encodes a transmembrane protein belonging to a family of proteins containing TLC domains, which are postulated to function in lipid synthesis, transport, or sensing. The protein localizes to the endoplasmic reticulum (ER), and may recycle between the ER and ER-Golgi intermediate compartment. Mutations in this gene are associated with progressive epilepsy with mental retardation (EMPR), which is a subtype of neuronal ceroid lipofuscinoses (NCL). Patients with mutations in this gene have altered levels of sphingolipid and phospholipids in the brain.

General readings

Hermansson,M., (2005) J. Neurochem. 95 (3), 609-617

6 Item(s)

per page

Primary Antibodies

Catalog No. Host Iso. Clone Pres. React. Applications  

CLN8 antibody

WB Suggested Anti-CLN8 Antibody Titration: 0.2-1 ug/ml; ELISA Titer: 1:12500; Positive Control: Hela cell lysate Rabbit IgG Purified Can, Eq, GP, Hu, Ms, Rt WB
50 µg / €325.00
  OriGene Technologies, Inc.

CLN8 antibody

WB Suggested Anti-CLN8 Antibody Titration: 0.2-1 ug/ml; ELISA Titer: 1:12500; Positive Control: 293T cell lysate; CLN8 is supported by BioGPS gene expression data to be expressed in HEK293T Rabbit IgG Purified Bov, Can, GP, Hu, Ms, Rb, Rt WB
50 µg / €325.00
  OriGene Technologies, Inc.

CLN8 antibody

Human HeLa; WB Suggested Anti-CLN8 Antibody Titration: 0.2-1 ug/ml. ELISA Titer: 1:12500. Positive Control: Hela cell lysate; CLN8 antibody - N-terminal region (ARP49408_P050) in Human HeLa cells using Western Blot Rabbit Aff - Purified Can, Hu WB
50 µg / €350.00
  AVIVA Systems Biology

CLN8 antibody

Human 293T; WB Suggested Anti-CLN8 Antibody Titration: 0.2-1 ug/ml. ELISA Titer: 1:12500. Positive Control: 293T cell lysate. CLN8 is supported by BioGPS gene expression data to be expressed in HEK293T.; CLN8 antibody - N-terminal region (ARP49409_P050) in Human 293T cells using Western Blot Rabbit Aff - Purified Bov, Can, Hu, Ms WB
50 µg / €350.00
  AVIVA Systems Biology

CLN8 antibody

CLN8 Rabbit Aff - Purified Can, Hu WB
50 µg / €440.00
  Novus Biologicals Inc.

CLN8 antibody

CLN8 Rabbit Aff - Purified Bov, Can, Hu, Ms WB
50 µg / €440.00
  Novus Biologicals Inc.

6 Item(s)

per page
  • LinkedIn